COMMUNIQUÉS West-GlobeNewswire

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
22/04/2026
BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certain business [...]
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
22/04/2026
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the [...]
Teknova to Report First Quarter 2026 Financial Results on May 6, 2026
22/04/2026
HOLLISTER, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22/04/2026
CHASKA, Minn., April 22, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that [...]
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor
22/04/2026
Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva’s organizational build-out as it advances toward potential commercialization. Axel-Sven Malkomes joins as Chief [...]
Altimmune Announces Proposed Underwritten Public Offering of Securities
22/04/2026
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced it has [...]
PetMeds announces strategic partnership with Rural King to launch pet pharmacy offering across retail and digital channels
22/04/2026
Collaboration expands access to affordable pet medications for rural communities nationwide DELRAY BEACH, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., doing business as PetMeds and parent company of [...]
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
22/04/2026
Pivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027 LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- [...]
George Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhage
22/04/2026
Significant lowering of systolic blood pressure of 9mmHg on top of background treatment maintained with GMRx2 over an average follow-up of 3 years Safety findings similar to previous studies of GMRx2 London, UK, Boston [...]
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
22/04/2026
ALISO VIEJO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the first quarter after the market close on Wednesday, May 6, 2026. The [...]
Sight Sciences Announces the Release of its Sustainability Report
22/04/2026
The Sustainability Report provides data for 2023 through 2025 on the Company’s environmental, social, and governance initiatives MENLO PARK, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT [...]
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
22/04/2026
HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous [...]
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
22/04/2026
BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines BBO-11818 demonstrates robust [...]
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée
22/04/2026
Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée Approbation pour les [...]
Mind Lab Pro Unveiled: Does This “Universal Nootropic” Really Improve Focus, Memory & Brain Power? Read Mind Lab PRO Report!
22/04/2026
Explore Mind Lab Pro’s science-backed formula, clinical insights & cognitive benefits. A complete guide to focus, memory & brain performance. New York City, NY, April 22, 2026 (GLOBE NEWSWIRE) -- In an era where [...]
Ipsen S.A. - Informations concernant la tenue de l’Assemblée Générale Mixte du 13 mai 2026
22/04/2026
Informations concernant la tenue de l’Assemblée Générale Mixte du 13 mai 2026 d’Ipsen S.A. Modalités de mise à disposition et de consultation des documents préparatoires à l’Assemblée PARIS, FRANCE, 22 AVRIL 2026 - [...]
EssilorLuxottica: Q1 2026 Revenue - Revenue rising 10.8% in Q1. Third consecutive quarter of double-digit growth
22/04/2026
Revenue rising 10.8% in Q1 Third consecutive quarter of double-digit growth Group revenue at Euro 7,127 million in Q1, up 10.8% at constant exchange rates 1 and +4.1% at current rates Both Professional Solutions and [...]
EssilorLuxottica: Chiffre d'affaires T1 2026 - Chiffre d'affaires en hausse de +10,8 % au premier trimestre. Troisième trimestre consécutif de croissance à deux chiffres
22/04/2026
Chiffre d'affaires en hausse de +10,8 % au premier trimestre Troisième trimestre consécutif de croissance à deux chiffres Chiffre d'affaires du Groupe à 7 127 millions d'euros au T1, en hausse de +10,8 % à taux de [...]
Ipsen S.A. - Information relating to the holding of the Combined Shareholders’ Meeting of 13 May 2026
22/04/2026
Information relating to the holding of the Combined Shareholders’ Meeting of 13 May 2026 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting PARIS, FRANCE, 22 APRIL 2026 - [...]

Pages